January 13, 2015

 Roche licenses investigational beta-lactamase inhibitor OP0595

 OP0595 targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics to enhance their effectiveness in difficult-to-treat bacterial infections

Roche (SIX: R...

Please reload

Featured Posts

Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates

January 16, 2017

Please reload

Recent Posts
Please reload

Please reload

Follow Us
  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

11629 – 105 Avenue, Edmonton, AB T5H 0L9  |   780-757-5401

© 2017 Fedora Pharmaceuticals Inc. 

  • Facebook - Black Circle
  • LinkedIn - Black Circle